Immunic, inc. to participate in scientific, industry and investor conferences in june

New york , june 8, 2022 /prnewswire/ -- immunic , inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in june: june 10-13: 13th international congress on autoimmunity. evelyn peelen, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking